Table 3 Univariate and multivariate analyses of clinical features and biomarkers with patients’ overall survival (cohort P)
From: Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma
Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
HR(95 % CI) | P value a | HR(95 % CI) | P valuea | ||
wtERa | high vs. low | 0.455 (0.202–1.025) | 0.058 | 0.519 (0.156–1.723) | 0.284 |
ERa36 | high vs. low | 1.070 (0.501–2.282) | 0.862 | 2.853 (0.843–9.654) | 0.092 |
ERb | high vs. low | 1.121 (0.524–2.402) | 0.768 | 1.151 (0.342–3.867) | 0.820 |
Age | >58 vs. ≤58 | 1.536 (0.698–3.380) | 0.286 | 1.767 (0.503–6.205) | 0.375 |
Gender | Female vs. Male | 0.314 (0.125–0.787) | 0.013 | 0.186 (0.047–0.733) | 0.016 |
AFP (ng/ml) | >18 vs. ≤18 | 0.896 (0.415–1.935) | 0.780 | 0.978 (0.327–2.925) | 0.969 |
Tumor number | Multiple vs. Single | 4.660 (2.069–10.495) | 0.000 | 2.065 (0.635–6.719) | 0.228 |
Tumor size (cm) | >5 vs. ≤5 | 3.528 (1.635–7.612) | 0.001 | 4.679 (1.441–15.195) | 0.010 |
Vascular invasion | Yes vs. No | 2.695 (1.165–6.231) | 0.020 | 0.282 (0.058–1.361) | 0.115 |
Intra-hepatic recurrence | Yes vs. No | 2.118 (0.967–4.640) | 0.061 | 0.718 (0.192–2.689) | 0.623 |
Extra-hepatic metastasis | Yes vs. No | 2.741 (1.216–6.181) | 0.015 | 2.177 (0.714–6.638) | 0.171 |
Neo-adjuvant treatments | Yes vs. No | 3.851 (1.121–13.230) | 0.032 | 2.132 (0.341–13.318) | 0.418 |
Adjuvant treatments | Yes vs. No | 4.522 (1.393–14.687) | 0.012 | 11.204 (2.231–56.266) | 0.003 |
Liver cirrhosis | Yes vs. No | 3.377 (1.258–9.062) | 0.016 | 5.202 (1.324–20.435) | 0.018 |
HBsAg | + vs. - | 0.542 (0.241–1.215) | 0.137 | 0.596 (0.153–2.317) | 0.455 |